- Vaccine Ontology ID: VO_0004726
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Preparation: A recombinant canarypox virus vector was used to co-express genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus (Boone et al., 2007).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004788
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Preparation: BTV recombinant capripoxviruses (BTV-Cpox) individually expressing four different genes encoding two capsid proteins (VP2 and VP7) and two non-structural proteins (NS1, NS3) of BTV serotype 2 (BTV-2) (Perrin et al., 2007).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004706
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Sheep
- Preparation: MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012)
- Immunization Route: Other
|
|
Sheep Response
- Vaccine Immune Response Type: VO_0000287
- Challenge Protocol: The field strain of BTV-17 was used for challenging (Boone et al., 2007).
- Efficacy: The sheep vaccinated with the recombinant canarypox virus vectored vaccine were resistant to challenge with a field strain of BTV-17 (Boone et al., 2007).
|
Sheep Response
- Vaccination Protocol: Sheep were immunized with BTV recombinant capripoxviruses (BTV-Cpox) (Perrin et al., 2007).
- Vaccine Immune Response Type: VO_0000287
- Challenge Protocol: The sheep were challenged with a virulent strain of BTV-2 (Perrin et al., 2007).
- Efficacy: Sheep challenged 3 weeks after BTV-Cpox vaccination exhibited partial protection (Perrin et al., 2007).
|
Sheep Response
- Vaccination Protocol: Sheep were injected twice with an MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012).
- Vaccine Immune Response Type: VO_0000287
- Immune Response: The SG33-VP2 vector promoted the production of neutralising antibodies (Maclachlan et al., 2009).
- Efficacy: The SG33-VP2 vector expressing VP2 partially protected sheep against disease after challenge with a highly virulent strain of serotype-8 bluetongue virus (BTV-8) (Top et al., 2012).
|
Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].
|
Perrin et al., 2007: Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine. 2007; 25(37-38); 6774-6783. [PubMed: 17669563].
|
Maclachlan et al., 2009: Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. Journal of comparative pathology. 2009; 141(1); 1-16. [PubMed: 19476953].
Top et al., 2012: Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine. 2012; 30(9); 1609-1616. [PubMed: 22244980].
|
